Consider running the follow searches in automatic batches so the relevant professional or group are notified about patients to review at appropriate interval. For more details on setting this up see Automated Reporting
Monthly Batch
| Search Name | Search Location | Search Return | Notes |
| ? Lipids 3.2 Management – Possible poor lipid lowering therapy concordance # | CDRC Quality > Lipids | Patients who don’t seem to be taking their prescribed lipid lowering | Contact patient to review concordance |
| Lipids > ? Statin Safety 1.0 – Any statin – potential contraindicated interaction # | CDRC Quality > Lipids | Patients with potential serious statin interactions. | Use Lipid Lowering Template to review potential serious interactions |
Quarterly Batch
| Search Name | Search Location | Search Returns | Notes |
| ? Statin Safety 3.0 – Any statin – consider dose in view of eGFR | CDRC Quality > Lipids | Patients who may need dose adjustments based on renal function | Review record. Consider suitability of statin dose given eGFR |
| ? Lipids 4.6 Consider remote statin intensification | CDRC Quality > Lipids | Patients who could have an electronic invite to consider statin intensification | |
| ? Lipids 1.04 Screening – Target for CVD Risk Assessment – estimated risk >20% | CDRC Quality > Lipids | Patients at highest risk of CVD who have not had a CVD risk assessment | Consider inviting for a CVD risk assessment. |
Annual Batch
| Search Name | Search Location | Search Returns | Notes |
| ? Lipids 2.0 Case Finding – Consider screening for familial hypercholesterolaemia # | CDRC Quality > Lipids | Patients who may have familial hypercholesterolaemia | Review record and refer if appropriate |
| ? Lipids 4.3 Management – On low/mod lipid lowering – consider intensification # | CDRC Quality > Lipids | Patients to consider for lipid lowering intensification | Review patient and consider intensification or recording maximally tolerated treatment |
| ? Lipids 4.4 Management – Consider intensification to very high intensity lipid lowering # | CDRC Quality > Lipids | Patients to consider for lipid lowering intensification (secondary prevention only) | Review patient and consider intensification or recording maximally tolerated treatment |
| ? Lipids 5.1 Management – Consider lipid lowering – May need more detailed input | CDRC Quality > Lipids | Patients with more complex lipid issues e.g. previous intolerance to statin AND ezetimibe | Review record and consider treatment/referral |
| ? Lipids 5.4 Management – Referral Criteria for PCSK9i – Consider referral | CDRC Quality > Lipids | Patients who might benefit from PCSK9i treatment | Consider offering a referral to local lipid clinic |
| Diabetes DM022 | Potential Fix – Consider adding SNOMED code for statin ADR | CDRC Contracting > QoF | Diabetic patients who are missing from the diabetes over 40 statin QoF indicator – with a record of an S1 adverse reaction to statin but no SNOMED code | Consider adding SNOMED code – no clinical benefit but helps with performance measures. |
| Diabetes DM023 | Potential Fix – Consider adding SNOMED code for statin ADR | CDRC Contracting > QoF | Diabetic patients who are missing from the diabetes and CVD statin QoF indicator – with a record of an S1 adverse reaction to statin but no SNOMED code | Consider adding SNOMED code – no clinical benefit but helps with performance measures. |